Impact of induction regimens on stem cell mobilization yields in newly diagnosed multiple myeloma
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Hematology"
DOI: 10.1007/s00277-025-06372-4
Abstract: Autologous stem cell transplantation (ASCT) is integral to treating newly diagnosed multiple myeloma (MM). While novel therapies improve response rates, they also hinder stem cell mobilization. This study evaluates the impacts of induction regimens on… read more here.
Keywords: newly diagnosed; mobilization; stem cell; cell ... See more keywords
Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease Results.
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood.2024027620
Abstract: Previous results from CASSIOPEIA (NCT02541383) demonstrated superior progression-free survival (PFS) and minimal residual disease (MRD) negativity with the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (VTd) induction/consolidation and with daratumumab maintenance versus observation in… read more here.
Keywords: daratumumab maintenance; consolidation; mrd negativity; vtd ... See more keywords
Efficacy of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.8017
Abstract: 8017 Background: In TE NDMM patients (pts), the CD38 monoclonal antibody DARA significantly reduced the risk of progression/death and improved stringent CR, ≥CR, and MRD-negative rates when added to VTd in the phase 3 CASSIOPEIA… read more here.
Keywords: post; mrd; vtd; dara ... See more keywords
Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients (pts) receiving daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.8042
Abstract: 8042 Background: High-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) is the standard of care in TE NDMM. In the phase 3 CASSIOPEIA study, D-VTd significantly improved stringent complete response (sCR), ≥CR, and minimal… read more here.
Keywords: pts receiving; mobilization; vtd; transplantation ... See more keywords